CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
7.62
-0.21 (-2.62%)
Apr 28, 2026, 11:27 AM EDT - Market open
CorMedix Revenue
In the year 2025, CorMedix had annual revenue of $311.71M with 617.03% growth. CorMedix had revenue of $128.62M in the quarter ending December 31, 2025, with 312.10% growth.
Revenue (ttm)
$311.71M
Revenue Growth
+617.03%
P/S Ratio
1.93
Revenue / Employee
$1,631,984
Employees
191
Market Cap
597.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 311.71M | 268.24M | 617.03% |
| Dec 31, 2024 | 43.47M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
| Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
| Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
| Dec 31, 2019 | 283.27K | -146.53K | -34.09% |
| Dec 31, 2018 | 429.80K | 100.47K | 30.51% |
| Dec 31, 2017 | 329.33K | 105.22K | 46.95% |
| Dec 31, 2016 | 224.11K | 13.98K | 6.65% |
| Dec 31, 2015 | 210.13K | 20.86K | 11.02% |
| Dec 31, 2014 | 189.27K | 187.27K | 9,358.97% |
| Dec 31, 2013 | 2.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 294.28M |
| Zevra Therapeutics | 106.47M |
| Sutro Biopharma | 102.48M |
| Prothena Corporation | 9.68M |
| Aclaris Therapeutics | 7.83M |
| Prime Medicine | 4.63M |
| Ocugen | 4.41M |
| Shattuck Labs | 1.00M |
CRMD News
- 22 hours ago - CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study - Benzinga
- 1 day ago - CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients - GlobeNewsWire
- 13 days ago - CorMedix Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 21 days ago - CorMedix to Participate in Needham Virtual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - CorMedix Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 6 weeks ago - CorMedix Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - CorMedix stock drops after earnings: is this dip a buy before key catalyst? - Invezz
- 7 weeks ago - CorMedix Earnings Call Transcript: Q4 2025 - Transcripts